Explore News
-
Fasting after 60: What You Need to Know
Intermittent fasting’s effects on health change significantly after age 60, posing unexpected risks
-
NIH Study Reveals Why 70% of Wegovy Users Hit Plateaus
New NIH research uncovers brain-level resistance to GLP-1 drugs like Ozempic and Wegovy, explaining weight…
-
70% of Patients Achieve Weight Loss with Semaglutide Post-Surgery
New research reveals that semaglutide, a GLP-1 receptor agonist, significantly aids weight loss in patients…
-
Retatrutide Yields 28% Weight Loss in 80 Weeks
Eli Lilly’s experimental drug retatrutide led to unprecedented weight reduction in trial participants, signaling a…
-
GLP-1 Medications Reduce Cardiovascular Risk by 20%
A landmark global study finds that GLP-1 drugs significantly lower the risk of heart attacks,…
-
78% of Users Report Reduced Food Cravings on GLP-1s
New research illuminates how drugs like Ozempic and Mounjaro suppress ‘food noise,’ transforming the way…
-
Ozempic Weight Loss Tied to Major Health Benefits, Study Reveals
New research shows that patients who lost the most weight on GLP-1 drugs like Ozempic…
-
GLP-1 Drugs Reshape Obesity Care, New Guidelines Urge Dietitian-Led Approach
New international consensus emphasizes multidisciplinary care as GLP-1 medications surge in use, highlighting the critic
-
80% More Likely to Sustain Rapid Weight Loss: Study
New clinical trial data from the European Congress on Obesity shows rapid weight loss leads…
-
Daily Pill Helps 80% Keep Weight Off Post-Injection, Study Finds
A new trial reveals orforglipron helps maintain weight loss and could reduce reliance on long-term…
